UNSPSC 51386015: Tazeprofen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S05RV1R3LZ. European Medicines Agency schedules Tazeprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10846MIG. Tazeprofen generally arises in the molecular formula C16H13NO2S.

UNSPSC 51386015 Tazeprofen is a Commodity code that sits at the lowest tier of the taxonomy, but recent state and local procurement activity tagged to this code shows little connection to tazeprofen specifically. Instead, issuing bodies have solicited naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription fulfillment capabilities—all products and services that fall outside tazeprofen's narrow scope as an individual pharmaceutical ingredient. The mismatch between the code's nominal designation and the work actually being procured suggests that state and local buyers are using this code as a catch-all for pharmaceutical procurement rather than as a targeted commodity classifier. When relevant opportunities do surface, they involve health departments, state health and human services commissions, and cooperative purchasing alliances buying pharmaceuticals and related delivery systems to support community health initiatives, substance-abuse response, and employee health plans.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Geographic spread is limited to these three states in the recent record, and no standout repeat buyers emerge from the opportunities posted.